1-3 of 3
Karen Gogat-Marchant
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Free
Cyrille Touzeau, Hanlon Sia, Sebastian Grosicki, Paz Ribas, Carmine Liberatore, Paula Rodriguez-Otero, Suzanne Trudel, Takashi Ikeda, Antonio Lazzaro, Karen Gogat-Marchant, Sharon T. Sullivan, Domenico Cieri, Eric Leip, Meletios Dimopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 2283.
https://doi.org/10.1182/blood-2025-2283
Published: 2025
Journal Articles

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

Free
Laurent Frenzel, Thomas Chalopin, Mohamad Mohty, Cyrille Touzeau, Caroline Jacquet, Andrea Pieragostini, Manon Sapet, Camille Villesuzanne, Deborah Assouan, Lydia Montes, Daniel Re, Olivier Allangba, Julie Gay, Murielle Roussel, Yong Chen, Guido Nador, Yves Brault, Sikha Dabo, Karen Gogat-Marchant, Elodie Priol, Pierre-Alexandre Squara, Aurore Perrot
Journal: Blood
Blood (2025) 146 (Supplement 1): 8151.
https://doi.org/10.1182/blood-2025-8151
Published: 2025
Journal Articles

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Free
Ja Min Byun, Meletios Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, Nina N. Green, Domenico Cieri, Hang Quach
Journal: Blood
Blood (2025) 146 (Supplement 1): 5845.
https://doi.org/10.1182/blood-2025-5845
Published: 2025